Gleysteen John J
Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Surg Obes Relat Dis. 2016 Feb;12(2):430-5. doi: 10.1016/j.soard.2015.10.074. Epub 2015 Oct 16.
The history of intragastric balloons (IGBs) began in 1985 with the Garren-Edwards Bubble. It was approved by the U.S. Food and Drug Administration (FDA) for temporary use as a weight loss device, but its manufacture was discontinued in 1988, and approval was withdrawn in 1992 because of significant complications and limited and recidivistic weight loss. A number of IGBs have appeared since that time, mostly originating in Europe or South America, but none has acquired FDA approval until recently; the ReShape Duo Integrated Dual Balloon System (ReShape Medical Inc., San Clemente, California) received FDA approval in August 2015. The conclusions of an important 1987 international conference on IGBs and the characteristics, effectiveness, and problems of most other IGBs are described in this text. The common purpose of these devices as preliminary interventions before gastric bariatric surgery and their favorable effects on this purpose are emphasized and may have played a key role in the FDA's change of outlook of the IGB.
胃内球囊(IGB)的历史始于1985年的加伦 - 爱德华兹气泡球囊。它被美国食品药品监督管理局(FDA)批准作为一种临时减肥装置使用,但在1988年停止生产,并于1992年撤回批准,原因是出现了严重并发症以及减肥效果有限且易复发。自那时以来出现了许多胃内球囊,大多起源于欧洲或南美洲,但直到最近才有一款获得FDA批准;重塑双球囊集成系统(ReShape Medical Inc.,加利福尼亚州圣克莱门特)于2015年8月获得FDA批准。本文描述了1987年关于胃内球囊的一次重要国际会议的结论以及大多数其他胃内球囊的特点、有效性和问题。强调了这些装置作为胃减肥手术前初步干预措施的共同目的及其在此目的上的有利影响,这可能在FDA对胃内球囊看法的转变中起到了关键作用。